Kite, a Gilead Company, And Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For The Treatment Of Cancer

SANTA MONICA, Calif. and RICHMOND, Calif., Feb. 22, 2018 /PRNewswire/ -- Kite, a Gilead Company (Nasdaq: GILD) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced the companies have entered into a worldwide collaboration using Sangamo's zinc finger nuclease (ZFN) technology...